Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.88 |
| ▸ | MAPT | P10636 | 2/20 | 0.79 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.76 |
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.74 |
| ▸ | HTT | P42858 | 2/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.66 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.66 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.66 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.66 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.65 |
| ▸ | RHOC | P08134 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30739929 | 1.00 | LMNA (1.00) | LMNAKCNK3MAPTP2RX1PTGS1 | |
| SCHEMBL4286068 | 0.92 | MAPT (0.94) | LMNAKCNK3MAPTP2RX1PTGS1 | |
| SCHEMBL28668959 | 0.91 | LMNA (0.83) | LMNAKCNK3MAPTP2RX1PTGS1 | |
| SCHEMBL4683413 | 0.90 | KCNK3 (0.88) | LMNAKCNK3MAPTP2RX1PTGS1 | |
| SCHEMBL24073967 | 0.90 | KCNK3 (0.82) | LMNAKCNK3MAPTP2RX1PTGS1 | |
| SCHEMBL2494871 | 0.89 | KCNK3 (0.81) | LMNAKCNK3MAPTP2RX1PTGS1 | |
| Hydrochloric Acid SCHEMBL29693050 | 0.89 | KCNK3 (0.86) | LMNAKCNK3MAPTP2RX1PTGS1 | |
| Hydrochloric Acid SCHEMBL2106595 | 0.88 | KCNK3 (0.79) | LMNAKCNK3MAPTP2RX1PTGS1 | |
| SCHEMBL13601058 | 0.88 | LMNA (0.78) | LMNAKCNK3MAPTP2RX1PTGS1 | |
| SCHEMBL30739967 | 0.88 | LMNA (0.78) | LMNAKCNK3MAPTP2RX1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | PÉCSI TUDOMÁNYEGYETEM (HU) | 2019-07-09 | — | — | US | claimed |
| EP-3194399-B1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PECSI TUDOMANYEGYETEM (HU) | 2019-04-10 | — | — | EP | claimed |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2017-09-14 | — | — | US | claimed |
| EP-3194399-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | Pécsi Tudományegyetem (HU) | 2017-07-26 | — | — | EP | claimed |
| WO-2016042349-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2016-03-24 | — | — | WO | claimed |
| CN-113445066-B | Method for electrochemically synthesizing ortho-trifluoromethyl substituted aniline by using continuous flow | 南京先进生物材料与过程装备研究院有限公司 | 2022-12-20 | — | — | CN | disclosed |
| CN-114222574-A | Inhibition of USP36 | 瓦洛健康股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-113445066-A | Method for electrochemically synthesizing ortho-trifluoromethyl substituted aniline by using continuous flow | 南京先进生物材料与过程装备研究院有限公司 | 2021-09-28 | — | — | CN | disclosed |
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | PÉCSI TUDOMÁNYEGYETEM (HU) | 2019-07-09 | — | — | US | disclosed |
| EP-3194399-B1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PECSI TUDOMANYEGYETEM (HU) | 2019-04-10 | — | — | EP | disclosed |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2017-09-14 | — | — | US | disclosed |
| EP-3194399-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | Pécsi Tudományegyetem (HU) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016042349-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | PÉCSI TUDOMÁNYEGYETEM (HU) | 2016-03-24 | — | — | WO | disclosed |
| US-7589089-B2 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20080058331-A1 | Inhibitors for GlyT-1 | HOFFMANN-LA ROCHE INC. | 2008-03-06 | — | — | US | disclosed |
| EP-0725302-B1 | A process of producing a polyimide block copolymer | JAPAN SYNTHETIC RUBBER CO LTD (JP) | 2002-04-03 | — | — | EP | disclosed |
| EP-0725302-A2 | A process of producing a polyimide block copolymer | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1996-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344032-B2 | Agents for treating neurogenic inflammation and neuropathic hyperalgesia related disorders | TRPV1, P2RX3, P2RX7 | LMNA 3011/4885KCNK3 485/4885MAPT 340/4885 |
| US-20080058331-A1 | Inhibitors for GlyT-1 | GLRA1, SLC1A2, AGXT | LMNA 2399/4885KCNK3 1594/4885MAPT 236/4885 |
| US-20170260187-A1 | NEW AGENTS FOR TREATING NEUROGENIC INFLAMMATION AND NEUROPATHIC HYPERALGESIA RELATED DISORDERS | TRPV1, P2RX3, P2RX4 | LMNA 2768/4885KCNK3 370/4885MAPT 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.